ArticleFrontiers in immunology2022

Anti-PD-1 antibodies, a novel treatment option for advanced chemoresistant pulmonary lymphoepithelioma carcinoma.

Na Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.